Essex Woodlands Sees Bigger Bets, More Devices with New $900m Fund
This article was originally published in Start Up
Essex Woodlands Health Ventures closes on $900 million fund, one of the health care industry's largest.
You may also be interested in...
Rox Medical, which is developing a device to improve the oxygenation of blood, raised $35 million in a Series C round.
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.